Mesenchymal Stem Cells

According to data from the US Department of Health and Human Services, heart disease is the leading cause of death in the United States (1). Medical experts are looking for new technologies and discoveries to more effectively treat heart disease. Methods include mechanical therapies such as prosthetic heart valves and drug therapies such as anticoagulants. Recently, the scientific community has made an exciting new discovery in developing stem cell based therapies.

Longeveron uses mesenchymal stem cells from bone marrow. They are known to participate in regulation and sometimes to relieve inflammation and to aid in promoting the repair mechanism of blood vessels. They may also make the body's own stem cells more active in a beneficial way. According to the federal government ClinicalTrials.gov there are currently 817 studies worldwide that are investigating the use of mesenchymal stem cells in humans, including knee injuries and ulcerative colitis. Inspection to investigate whether cat mesenchymal stem cells can reduce cat inflammation

Umbilical cord tissue can be harvested at the same time as umbilical cord blood and contains another stem cell called mesenchymal stem cell (MSC). Mesenchymal stem cells are characterized by the ability to inhibit inflammation after tissue injury, secretion of growth factors that contribute to tissue repair, and differentiation into many cell types including neuronal cells, bone cells, adipocytes, and cartilage Has its own function. Umbilical tissue derived MSCs are increasingly used in regenerative medicine for a wide range of conditions, including heart and kidney disease, ALS, MS, Alzheimer's disease, wound healing and autoimmune diseases. Many clinical trials are already in progress and the use of MSC for stem cell therapy is being investigated. MSCs from umbilical cord blood and umbilical cord tissue are safe, easy to collect, and are a readily available source of stem cells. Cryo-Cell also provides umbilical cord tissue banking services and umbilical cord blood banks.

The body's immune system does not recognize that umbilical cord mesenchymal stem cells are exogenous, so they are not rejected. HUCT stem cells have been performed thousands of times at the stem cell research institute and have never been rejected (graft-versus-host disease). In fact, allogeneic (non-patient) mesenchymal stem cells are approved for the treatment of graft-versus-host disease in Canada and New Zealand. In the next video (over a minute), Dr. Arnold Caplan explained the mechanism by which donor mesenchymal stem cells protect themselves from the recipient's immune system. Dr. Kaplan is a scientist who discovered mesenchymal stem cells. He is often referred to as the "father of mesenchymal stem cells".